← All trials
NCT05332730
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 22, 2022
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Apr 18, 2022
- Last posted
- Apr 18, 2022
- Enrollment
- 375
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- BiotheraLead sponsor
- Jinlin UniversityCollaborator
- Jinlin UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.